Table 4.
Comparison of treatment outcomes with cefazolin and nafcillin for methicillin-susceptible S. aureus bacteremiaa
| Characteristic | Value for group |
P value | |
|---|---|---|---|
| Cefazolin treatment (n = 41) | Nafcillin treatment (n = 41) | ||
| Mean time to defervescence (days) ± SD | 4.1 ± 3.8 | 5.4 ± 9.5 | 0.62 |
| No. (%) of patients with: | |||
| Treatment failure at 4 wk | 4 (10) | 4 (10) | >0.99 |
| Antibiotic change due to clinical failure | 4 (10) | 0 (0) | 0.13 |
| Relapse | 0 | 0 | |
| SAB-related death | 0 (0) | 4 (10) | 0.13 |
| Treatment failure at 12 wk | 6 (15) | 6 (15) | >0.99 |
| Antibiotic change due to clinical failure | 4 (10) | 0 (0) | 0.13 |
| Relapse | 1 (2) | 1 (2) | >0.99 |
| SAB-related deaths | 1 (2) | 5 (12) | 0.22 |
| Overall mortality at 4 wk | 4 (10) | 4 (10) | >0.99 |
| Treatment interruption due to adverse drug event | 0 (0) | 7 (17) | 0.02 |
a
The study included 1:1 propensity-score-matched patients.